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Clinics and pathology 
Disease 
T-cell/histiocyte-rich large B cell lymphoma 
(THRLBCL) is a distinct entity of aggressive 
lymphoma, recognized by the WHO classification as a 
separate entity (2008), in which few scattered 
neoplastic cells (usually <5%) are surrounded by 
reactive T-lymphocytes and histiocytes. THRLBCL 
shares several morphological and immunophenotypic 
similarities with nodular lymphocyte-predominant 
Hodgkin's lymphoma (Pittaluga et al., 2010). These 
two entities may share initial transforming events that 
occur at germinal center B cell, followed by early 
divergence in the evolution of the neoplastic process 
(Franke et al., 2002). 
Phenotype/cell stem origin 
The postulated normal counterpart is a germinal centre 
B cell. 
The immunophenotype of the neoplastic component in 
pan-B positive, BCL6+, CD15-, CD30-. 
Epidemiology 
It accounts for a minority of diffuse large B-cell 
lymphoma (<10%). 
Clinics 
The disease runs an aggressive course and is usually 
associated with poor outcome in those patients 
presenting at an advanced stage. 
Pathology 
The lymph node section shows scattered large cells 
surrounded by many lymphocytes and histiocytes. The 
disease must be distinguished from nodular 
 
lymphocyte-predominant Hodgkin's lymphoma, which 
has distinct clinical features. 
Treatment 
Chemoimmunotherapy using anti CD20 monoclonal 
antibody rituximab in combination with CHOP or 
CHOP-like regimens is the standard of care (El Weshi 
et al., 2007). 
Prognosis 
A >80% overall response rate was obtained by 
chemoimmunotherapy, with a 5-year overall survival of 
approximately 50% (El Weshi et al., 2007). 
Cytogenetics 
Cytogenetics molecular 
Because of the low number of neoplastic cells, there are 
technical problems in obtaining evaluable metaphase 
chromosomes in THRLBCL. Tetraploid clones with 
complex aberrations, including a 14q32 translocation, 
were described in the absence of BCL6, BCL2 or c-
myc involvement (La Starza et al., 1996; Wang et al., 
2005; de Leval et al., 2006). 
The presence of the PAX5/IGH gene rearrangement 
was demonstrated by fluorescence in situ hybridization 
(FISH) to represent a recurrent aberration (Poppe et al., 
2005). 
An average of 4.7 genomic imbalances/case were 
detected by comparative genomic hybridization in 17 
cases of THRLBCL. The most frequently detected 
imbalances included gain of Xq (59%, minimal 
overlapping region Xq12q13), 4q (41%, minimal 
overlapping region 4q25q26), Xp (29%, minimal 
overlapping region Xp21p11), and 18q (24%, minimal 
overlapping region 18q21), as well as loss of 17p 
(24%) (Franke et al., 2002). 
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